Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis

Treatment gaps in the care of amyotrophic lateral sclerosis in the Philippines: A scoping review

“…As of July 2023, there were only four indexed research studies on ALS from the Philippines [ [10] , [11] , [12] , [13] ]. Five of the included articles in this study investigated ALS in Filipino populations but were not authored by Filipinos nor affiliated with Philippine institutions [ [14] , [15] , [16] , [17] , [18] ].…”

“…The recently approved drug for ALS, sodium phenylbutyrate + taurursodiol, is also not yet available in the country for commercial or compassionate use. The lack of available proven treatment options in the country may be reason why two of the included studies are systematic reviews evaluating the utility of perampanel and mexiletine in treating ALS [ 11 , 13 ]. In the study by Adiao and colleagues, three randomized trials were analyzed on the effect of mexiletene on ALS functional rating scale revised (ALSFRS-R), ALS impairment, survival, muscle cramps, and safety and tolerability.…”

Neuronal Circuit Dysfunction in Amyotrophic Lateral Sclerosis

“…Talampanel, an AMPAR antagonist showed a moderate effect on muscle function and strength in a small phase 2 study but did not show significant effect in a larger trial [149]. Another AMPAR antagonist, perampanel, prolonged motor neuronal survival and function in preclinical mouse model [150] but when used in the clinical trials led to adverse events in ALS patients, such as aggression, somnolence, and dysarthria [151]. These adverse events could be due to perturbed AMPAR levels in other regions of the central nervous system (CNS) by the AMPAR antagonists.…”